Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

GeneDx Holdings (WGSWW) EBIAT (2020 - 2025)

GeneDx Holdings has reported EBIAT over the past 6 years, most recently at -$17.7 million for Q4 2025.

  • Quarterly results put EBIAT at -$17.7 million for Q4 2025, down 424.86% from a year ago — trailing twelve months through Dec 2025 was -$21.0 million (up 59.8% YoY), and the annual figure for FY2025 was -$21.0 million, up 59.8%.
  • EBIAT for Q4 2025 was -$17.7 million at GeneDx Holdings, down from -$7.6 million in the prior quarter.
  • Over the last five years, EBIAT for WGSWW hit a ceiling of $32.7 million in Q3 2021 and a floor of -$308.8 million in Q4 2022.
  • Median EBIAT over the past 5 years was -$34.7 million (2021), compared with a mean of -$52.2 million.
  • Biggest five-year swings in EBIAT: skyrocketed 157.81% in 2021 and later tumbled 668.35% in 2022.
  • GeneDx Holdings' EBIAT stood at -$40.2 million in 2021, then tumbled by 668.35% to -$308.8 million in 2022, then skyrocketed by 91.65% to -$25.8 million in 2023, then surged by 121.1% to $5.4 million in 2024, then plummeted by 424.86% to -$17.7 million in 2025.
  • The last three reported values for EBIAT were -$17.7 million (Q4 2025), -$7.6 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.